Judith Christina Maro, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Product Surveillance, Postmarketing | 14 | 2024 | 452 | 4.480 |
Why?
|
Herpes Zoster Vaccine | 3 | 2023 | 49 | 2.220 |
Why?
|
Pharmacoepidemiology | 6 | 2024 | 350 | 2.030 |
Why?
|
Herpes Zoster | 3 | 2023 | 251 | 1.920 |
Why?
|
United States Food and Drug Administration | 15 | 2024 | 1677 | 1.220 |
Why?
|
Adverse Drug Reaction Reporting Systems | 7 | 2024 | 488 | 0.990 |
Why?
|
Data Mining | 8 | 2023 | 553 | 0.970 |
Why?
|
Pregnancy Outcome | 3 | 2024 | 2907 | 0.880 |
Why?
|
Guillain-Barre Syndrome | 2 | 2022 | 125 | 0.830 |
Why?
|
Databases, Factual | 15 | 2024 | 8035 | 0.820 |
Why?
|
Urticaria | 1 | 2022 | 150 | 0.760 |
Why?
|
Sentinel Surveillance | 6 | 2024 | 293 | 0.690 |
Why?
|
Papillomavirus Vaccines | 3 | 2021 | 495 | 0.690 |
Why?
|
Vaccination | 6 | 2023 | 3361 | 0.660 |
Why?
|
Pain, Intractable | 1 | 2020 | 132 | 0.650 |
Why?
|
Vaccines, Attenuated | 2 | 2019 | 314 | 0.630 |
Why?
|
Food | 1 | 2023 | 771 | 0.620 |
Why?
|
Exanthema | 1 | 2022 | 504 | 0.600 |
Why?
|
Vaccines | 3 | 2014 | 832 | 0.570 |
Why?
|
Propensity Score | 6 | 2022 | 1928 | 0.560 |
Why?
|
Research Design | 4 | 2024 | 6180 | 0.550 |
Why?
|
Insurance Claim Review | 2 | 2024 | 738 | 0.540 |
Why?
|
Drug Interactions | 1 | 2020 | 1428 | 0.500 |
Why?
|
Dermatitis, Atopic | 1 | 2022 | 716 | 0.500 |
Why?
|
Myocarditis | 1 | 2022 | 766 | 0.500 |
Why?
|
Drug Approval | 2 | 2020 | 816 | 0.480 |
Why?
|
Papillomavirus Infections | 3 | 2021 | 1607 | 0.460 |
Why?
|
Orphan Drug Production | 1 | 2014 | 48 | 0.460 |
Why?
|
Drug Monitoring | 1 | 2019 | 965 | 0.420 |
Why?
|
Cardiovascular Agents | 1 | 2019 | 867 | 0.420 |
Why?
|
Models, Immunological | 1 | 2014 | 513 | 0.410 |
Why?
|
Risk | 4 | 2019 | 9631 | 0.400 |
Why?
|
International Classification of Diseases | 3 | 2021 | 894 | 0.380 |
Why?
|
Computer Communication Networks | 3 | 2020 | 294 | 0.380 |
Why?
|
Influenza, Human | 3 | 2023 | 1528 | 0.380 |
Why?
|
Pharmaceutical Preparations | 4 | 2023 | 1091 | 0.370 |
Why?
|
Data Collection | 1 | 2020 | 3315 | 0.370 |
Why?
|
Warfarin | 1 | 2019 | 1518 | 0.350 |
Why?
|
United States | 24 | 2024 | 72461 | 0.340 |
Why?
|
Rare Diseases | 1 | 2014 | 619 | 0.320 |
Why?
|
Seizures | 2 | 2019 | 2917 | 0.320 |
Why?
|
Cohort Studies | 10 | 2024 | 41335 | 0.300 |
Why?
|
Incidence | 6 | 2021 | 21392 | 0.290 |
Why?
|
Sample Size | 2 | 2022 | 840 | 0.260 |
Why?
|
Electronic Health Records | 8 | 2024 | 4775 | 0.260 |
Why?
|
Computer Simulation | 3 | 2014 | 6218 | 0.240 |
Why?
|
Nitrosamines | 1 | 2024 | 87 | 0.240 |
Why?
|
Analgesics, Opioid | 1 | 2020 | 3763 | 0.230 |
Why?
|
Humans | 48 | 2024 | 760621 | 0.220 |
Why?
|
Papillomaviridae | 2 | 2021 | 1117 | 0.220 |
Why?
|
Models, Statistical | 3 | 2014 | 5075 | 0.220 |
Why?
|
Registries | 2 | 2022 | 8469 | 0.220 |
Why?
|
Drug Contamination | 1 | 2024 | 152 | 0.220 |
Why?
|
Medical Records Systems, Computerized | 1 | 2009 | 1191 | 0.210 |
Why?
|
Herpesvirus 3, Human | 1 | 2023 | 158 | 0.200 |
Why?
|
Health Services Research | 1 | 2009 | 1810 | 0.200 |
Why?
|
Losartan | 1 | 2023 | 265 | 0.190 |
Why?
|
Pregnancy Trimester, First | 2 | 2022 | 908 | 0.190 |
Why?
|
Anticonvulsants | 2 | 2022 | 1879 | 0.190 |
Why?
|
Respiratory Syncytial Virus, Human | 1 | 2023 | 149 | 0.180 |
Why?
|
Oxymorphone | 1 | 2020 | 6 | 0.180 |
Why?
|
Data Interpretation, Statistical | 2 | 2021 | 2696 | 0.170 |
Why?
|
Drug Evaluation | 1 | 2021 | 641 | 0.170 |
Why?
|
Decision Making, Organizational | 1 | 2020 | 136 | 0.170 |
Why?
|
Vaccines, Synthetic | 1 | 2022 | 617 | 0.160 |
Why?
|
Incretins | 1 | 2019 | 103 | 0.160 |
Why?
|
Oxycodone | 1 | 2020 | 138 | 0.160 |
Why?
|
Stillbirth | 1 | 2022 | 368 | 0.160 |
Why?
|
Software | 2 | 2018 | 4419 | 0.160 |
Why?
|
Live Birth | 1 | 2022 | 512 | 0.150 |
Why?
|
Contraceptives, Oral, Combined | 1 | 2018 | 116 | 0.150 |
Why?
|
Time Factors | 6 | 2021 | 40165 | 0.150 |
Why?
|
Myocardial Infarction | 1 | 2019 | 11891 | 0.150 |
Why?
|
Pandemics | 3 | 2021 | 8624 | 0.140 |
Why?
|
Technology | 1 | 2019 | 291 | 0.140 |
Why?
|
Hypoglycemic Agents | 2 | 2019 | 3150 | 0.140 |
Why?
|
Diabetic Ketoacidosis | 1 | 2019 | 257 | 0.130 |
Why?
|
Cluster Analysis | 1 | 2022 | 2698 | 0.130 |
Why?
|
Pregnancy | 5 | 2024 | 29749 | 0.120 |
Why?
|
Birth Weight | 1 | 2022 | 2097 | 0.110 |
Why?
|
Medical Records | 1 | 2019 | 1407 | 0.110 |
Why?
|
Seizures, Febrile | 1 | 2014 | 108 | 0.110 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2021 | 1375 | 0.110 |
Why?
|
Infant | 4 | 2022 | 36060 | 0.110 |
Why?
|
Canada | 3 | 2024 | 2128 | 0.110 |
Why?
|
Pancreatitis | 1 | 2019 | 1100 | 0.100 |
Why?
|
Mothers | 1 | 2022 | 2186 | 0.100 |
Why?
|
Algorithms | 5 | 2021 | 13981 | 0.100 |
Why?
|
Denmark | 2 | 2024 | 760 | 0.100 |
Why?
|
Epidemiologic Research Design | 1 | 2014 | 368 | 0.090 |
Why?
|
Poisson Distribution | 1 | 2011 | 507 | 0.090 |
Why?
|
Electronics | 2 | 2022 | 315 | 0.090 |
Why?
|
Hyperlipoproteinemia Type II | 1 | 2014 | 396 | 0.080 |
Why?
|
Pilot Projects | 2 | 2020 | 8555 | 0.080 |
Why?
|
Female | 14 | 2024 | 391270 | 0.080 |
Why?
|
Anaphylaxis | 1 | 2015 | 755 | 0.080 |
Why?
|
Kidney Diseases | 1 | 2019 | 2093 | 0.080 |
Why?
|
Influenza Vaccines | 1 | 2015 | 766 | 0.080 |
Why?
|
Observation | 1 | 2009 | 312 | 0.070 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2020 | 2290 | 0.070 |
Why?
|
Monte Carlo Method | 1 | 2011 | 1257 | 0.070 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2018 | 2003 | 0.070 |
Why?
|
Proportional Hazards Models | 1 | 2020 | 12531 | 0.070 |
Why?
|
Financing, Government | 1 | 2009 | 472 | 0.060 |
Why?
|
Venous Thromboembolism | 1 | 2018 | 1864 | 0.060 |
Why?
|
Reproducibility of Results | 2 | 2024 | 20080 | 0.060 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2019 | 3455 | 0.060 |
Why?
|
Young Adult | 6 | 2021 | 58741 | 0.060 |
Why?
|
Drug Recalls | 1 | 2024 | 20 | 0.060 |
Why?
|
Logistic Models | 1 | 2019 | 13314 | 0.060 |
Why?
|
Risk Assessment | 2 | 2019 | 24123 | 0.060 |
Why?
|
HIV Infections | 2 | 2020 | 17165 | 0.050 |
Why?
|
Prospective Studies | 4 | 2021 | 54303 | 0.050 |
Why?
|
Adolescent | 6 | 2021 | 87810 | 0.050 |
Why?
|
Hypertension | 1 | 2023 | 8594 | 0.050 |
Why?
|
Infant, Newborn | 1 | 2022 | 26181 | 0.050 |
Why?
|
Treatment Outcome | 2 | 2021 | 65017 | 0.050 |
Why?
|
Hospitalization | 1 | 2021 | 10790 | 0.050 |
Why?
|
Decision Making | 1 | 2014 | 3925 | 0.050 |
Why?
|
Patient Acceptance of Health Care | 1 | 2014 | 3164 | 0.050 |
Why?
|
Aged | 4 | 2024 | 169152 | 0.040 |
Why?
|
Adult | 8 | 2024 | 219994 | 0.040 |
Why?
|
Male | 8 | 2024 | 359744 | 0.040 |
Why?
|
Biological Therapy | 1 | 2021 | 139 | 0.040 |
Why?
|
Clinical Coding | 1 | 2021 | 181 | 0.040 |
Why?
|
Glycosides | 1 | 2019 | 111 | 0.040 |
Why?
|
Sensitivity and Specificity | 1 | 2014 | 14660 | 0.040 |
Why?
|
Biphenyl Compounds | 1 | 2023 | 992 | 0.040 |
Why?
|
Predictive Value of Tests | 1 | 2014 | 15289 | 0.040 |
Why?
|
Child | 3 | 2021 | 79806 | 0.040 |
Why?
|
Tetrazoles | 1 | 2023 | 905 | 0.040 |
Why?
|
Fertility | 1 | 2022 | 773 | 0.040 |
Why?
|
Middle Aged | 6 | 2024 | 220352 | 0.030 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2023 | 1031 | 0.030 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2023 | 1523 | 0.030 |
Why?
|
Heart Failure | 1 | 2019 | 11847 | 0.030 |
Why?
|
Vaccines, Inactivated | 1 | 2015 | 180 | 0.030 |
Why?
|
Communicable Disease Control | 1 | 2021 | 844 | 0.030 |
Why?
|
Immunization | 1 | 2018 | 1227 | 0.030 |
Why?
|
Prevalence | 2 | 2021 | 15687 | 0.030 |
Why?
|
Gestational Age | 1 | 2022 | 3565 | 0.030 |
Why?
|
HIV | 1 | 2020 | 1579 | 0.030 |
Why?
|
Retrospective Studies | 4 | 2024 | 80372 | 0.030 |
Why?
|
Statistics as Topic | 1 | 2018 | 2362 | 0.020 |
Why?
|
Risk Factors | 2 | 2018 | 74359 | 0.020 |
Why?
|
Natural Language Processing | 1 | 2019 | 1135 | 0.020 |
Why?
|
Health Policy | 1 | 2021 | 2677 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2021 | 3061 | 0.020 |
Why?
|
Inpatients | 1 | 2018 | 2581 | 0.020 |
Why?
|
Biomedical Research | 1 | 2020 | 3426 | 0.020 |
Why?
|
Anti-HIV Agents | 1 | 2019 | 4491 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2024 | 58995 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2018 | 7818 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2019 | 39261 | 0.010 |
Why?
|
Child, Preschool | 1 | 2015 | 42063 | 0.010 |
Why?
|